Coagulation Disorder, BloodSONALGNCT03482128
Blood Transfusion and Postoperative Outcome Before and After Implementing a Coagulation Management Algorithm
An observational study of Coagulation Disorder, Blood, run by Triemli Hospital at 1 site in Switzerland.
Trial summary
Implementing coagulation management algorithms based on Point-of-care (POC) testing devices such as thromboelastography (TEG) or rotational thromboelastometry (ROTEM) have been shown to reduce transfusion rates and the occurrence of adverse patient outcomes. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Coagulation Disorder, Blood
- What is being tested?
- Coagulation management guided by SONOCLOT and Standard coagulation management
- Type of treatment
- Medical device
- How many people
- 1,754 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jan 2011to 31 Dec 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients undergoing cardiac surgery at the Triemli City Hospital
Who may be able to join
- Patients undergoing cardiac surgery at the Triemli City Hospital
- Coronary artery bypass grafting
- Valve intervention (Aortic/Mitral/Tricuspid)
- Aortic surgery
- Time period before implementation of a coagulation management guided by SONOCLOT
- Time period after implementation of a coagulation management guided by SONOCLOT
Who cannot join
- Time period during implementation of a coagulation management guided by SONOCLOT
- Missing data in data base
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Allogeneic Blood Transfusion and Postoperative Outcome Before and After Implementing a SONOCLOT Based Coagulation Management Algorithm in Cardiac Surgery: A Quality Control Study
Implementing coagulation management algorithms based on Point-of-care (POC) testing devices such as thromboelastography (TEG) or rotational thromboelastometry (ROTEM) have been shown to reduce transfusion rates and the occurrence of adverse patient outcomes. Apart from the TEG and ROTEM, another viscoelastic POC measurement technique, the SONOCLOT, can be easily used at the bedsite. However Information regarding a SONOCLOT based coagulation management algorithm however is lacking.
Transfusion rates of allogeneic blood products (Red blood cells = RBC, Fresh frozen plasma = FFP, Platelet concentrates = PLT) and patient adverse outcomes in two cohorts before and after the implementation of a SONOCLOT based coagulation management algorithm were evaluated on an observational basis in 1754 patients undergoing different types of cardiac surgery. The effect of the cohort and 19 predictors on transfusion was assessed by relative R2-values obtained by bootstrapping and a hurdle regression model, comprising a binomial and a Poisson count component. Association of predictors with post-operative outcomes was assessed with a logistic regression model.
Read the detailed description
Patient data and all relevant procedure related data of cardiac surgery procedures at the Triemli City Hospital, Switzerland are recorded in a dedicated database with the approval of the institutional research ethics board and patient informed consent. Data analysis focusing on coagulation management using a dedicated algorithm in the present quality control study is done for 1754 out of 2199 consecutive patients undergoing cardiac surgery comprising the initial cohort from 2009 to 2011 (before implementation of the algorithm) and the subsequent cohort from 2013 to 2015 (after implementation of the algorithm).
In the time period analyzed for this study anesthesia and intensive care were performed according to standardized protocols. Fluid management was done with lactated Ringer's solution and synthetic colloids. Different blood conservation strategies were used and included consistently cell salvage, standardized application of tranexamic acid and retrograde autologous cardiopulmonary bypass (CPB) priming. Anticoagulant medication was suspended at least 5 days prior to surgery for all elective procedures. Hematocrit measurements were performed using a standard POC blood gas analyzer available in the OR. Indication for red blood cells (RBC) transfusion were a hematocrit (HCT) level below 21% during CPB, below 25% for patients with preserved left ventricular function and 28% for patients with a left ventricular function ≤ 30% and patients undergoing emergency procedures. Standard laboratory tests (blood count, international normalized ratio (INR) / prothrombin time (PT), activated partial thromboplastin time (aPTT) fibrinogen concentration (FIB) were routinely available for guiding transfusion of coagulation blood products. Coagulation management before the implementation of the algorithm was performed based on institutional guidelines in accordance with published recommendations. Kaolin activated clotting time (ACT) measurements were used to guide heparin and protamine management. After heparin reversal and ongoing bleeding prothrombin complex concentrate was applied at a PT ≤ 70% / INR threshold of 1.5 and in selected cases with ongoing major bleeding fresh frozen plasma (FFP) was used to normalize PT/INR. Moreover, fibrinogen concentrate was given below a fibrinogen level of 1 g/l. Platelet concentrates (PLT) were transfused when platelet count was ≤ 100 x 109/lit. PLT were also given in suspected platelet dysfunction. When severe bleeding occurred at the end of the surgical procedure coagulation management was started on an empirical basis by the anesthesiologist in charge.
The SONOCLOT coagulation management algorithm is based on existing literature on this subject and the experience of the authors with the specific POC technique: It considers standard coagulation lab results and platelet function tests and includes the use of the MULTIPLATE analyzer. SONOCLOT measurements consist basically of three dedicated tests:
- A kaolin ACT that is being applied for heparin and protamine administration.
- A glass-bead ACT providing information about the initiation of the clotting process, the propagation of the coagulation and platelet function.
- A glass-bead ACT with heparinase in case the measurement has to be performed under heparin.
First coagulation measurements in each patient undergoing cardiac surgery are executed in the pre-intervention period. The established baseline values trigger the preparation of coagulation blood products that will be applied in the post-interventional period. At the end of the surgical procedure, heparin reversal is performed according to the Bulls protocol. After initial antagonisation with protamine kaolin ACT and glass-bead ACT as well as a heparinase glass-bead ACT are done to primarily detect any residual heparin. For any registered serum heparin the treatment and measurement loop is repeated. In case of an ongoing bleeding after heparin reversal a surgery-related cause has to be excluded and then another treatment and management loop based on glass-bead ACT is initiated and repeated until coagulation has been restored. As soon as results of the standard lab test are available in the postoperative period these are included in the decision making process.
Primary outcome parameters were transfusion rates during the operation and the treatment in the ICU. Secondary outcome parameters included morbidity: an mortality in the postoperative period during the hospital stay.
Statistical analysis will be performed with the software package R. To compare patient-related demographic and perioperative data prior and post algorithm implementation and univariable analysis are performed. Based on the data format and distribution, either Fisher's exact test, t-tests or Wilcoxon rank sum test were applied. For the assessment of the difference of transfusion in the two cohorts and controlling potential influence of other factors two approaches have been chosen. First, after a continuity-corrected log-transformation of the units of RBC given, a sequence of preoperative and procedure related predictors were included in the analysis. To check for multi-colinearity, variance inflation factors are assessed with the R package. Furthermore, to assess the association between potential risk factors and the incidence of postoperative infections a generalized linear model with a binomial link and logit function was chosen and performed with the R package.
- Conditions
- Coagulation Disorder, Blood
- Being tested
- Coagulation management guided by SONOCLOT, Standard coagulation management
- Keywords
- transfusion, coagulation, cardiac surgery
- Medical subject headings
- Blood Coagulation Disorders, Thrombosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Coagulation management guided by SONOCLOTDevice
Application of blood products guided by SONOCLOT measurements
Standard coagulation managementDevice
Application of blood products based on clinical experience of the anesthesiologist in charge
| Study group | Role | What they receive |
|---|---|---|
| preAlgorithm | Standard coagulation management of patients undergoing cardiac surgery Receives: Device: Standard coagulation management | |
| postAlgorithm | Coagulation management guided by SONOCLOT of patients undergoing cardiac surgery Receives: Device: Coagulation management guided by SONOCLOT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Transfusion requirement
RBC-Red Blood Cells (units), FFP-Fresh Frozen Plasma (units), PLT-Platelets (units)
Measured: Postoperative hospital stay; on average 8 days
Secondary outcomes (2)
Postoperative complications
Infections, myocardial infarction, cerebrovascular insult, acute renal failure
Measured: Postoperative hospital stay; on average 8 days
Mortality
Death
Measured: Postoperative hospital stay; on average 8 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Mar 2018
- Study start1 Jan 2011
- Primary completion31 Dec 2015
- Study completion31 Dec 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Coagulation Disorder, BloodStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,754 participants (actual)
Sponsor and investigators
- Lead sponsor
- Triemli Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University of Zurich
- Responsible party
- Principal investigator, Christoph K Hofer, Triemli Hospital
- Investigators
- Michele Genoni, MD, Prof, Study chair, Triemli City Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03482128
- Sponsor's protocol ID
- STZ-Dendrite11-15
- Acronym
- SONALG
- Status last verified
- May 2018
- First submitted
- 8 Mar 2018
- Last updated
- 18 May 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Serraino GF, Murphy GJ. Routine use of viscoelastic blood tests for diagnosis and treatment of coagulopathic bleeding in cardiac surgery: updated systematic review and meta-analysis. Br J Anaesth. 2017 Jun 1;118(6):823-833. doi: 10.1093/bja/aex100.
PubMed 28475665Deppe AC, Weber C, Zimmermann J, Kuhn EW, Slottosch I, Liakopoulos OJ, Choi YH, Wahlers T. Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res. 2016 Jun 15;203(2):424-33. doi: 10.1016/j.jss.2016.03.008. Epub 2016 Mar 26.
PubMed 27363652Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Kleijnen J. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015 Jul;19(58):1-228, v-vi. doi: 10.3310/hta19580.
PubMed 26215747
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Allogeneic Blood Transfusion and Postoperative Outcome Before and After Implementing a SONOCLOT Based Coagulation Management Algorithm in Cardiac Surgery: A Quality Control Study
- ClinicalTrials.gov ID
- NCT03482128
- Acronym / sponsor ID
- SONALG / STZ-Dendrite11-15
- Conditions
- Coagulation Disorder, Blood
- Keywords
- transfusion, coagulation, cardiac surgery
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,754 participants (actual)
- Lead sponsor
- Triemli HospitalUniversity, hospital or other
- Collaborators
- University of Zurich
- Study start
- 1 Jan 2011 (actual)
- Primary completion
- 31 Dec 2015 (actual)
- Study completion
- 31 Dec 2015 (actual)
- First posted
- 29 Mar 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Implementing coagulation management algorithms based on Point-of-care (POC) testing devices such as thromboelastography (TEG) or rotational thromboelastometry (ROTEM) have been shown to reduce transfusion rates and the occurrence of adverse patient outcomes. Apart from the TEG and ROTEM, another viscoelastic POC measurement technique, the SONOCLOT, can be easily used at the bedsite. However Information regarding a SONOCLOT based coagulation management algorithm however is lacking.
Transfusion rates of allogeneic blood products (Red blood cells = RBC, Fresh frozen plasma = FFP, Platelet concentrates = PLT) and patient adverse outcomes in two cohorts before and after the implementation of a SONOCLOT based coagulation management algorithm were evaluated on an observational basis in 1754 patients undergoing different types of cardiac surgery. The effect of the cohort and 19 predictors on transfusion was assessed by relative R2-values obtained by bootstrapping and a hurdle regression model, comprising a binomial and a Poisson count component. Association of predictors with post-operative outcomes was assessed with a logistic regression model.
Detailed description
Patient data and all relevant procedure related data of cardiac surgery procedures at the Triemli City Hospital, Switzerland are recorded in a dedicated database with the approval of the institutional research ethics board and patient informed consent. Data analysis focusing on coagulation management using a dedicated algorithm in the present quality control study is done for 1754 out of 2199 consecutive patients undergoing cardiac surgery comprising the initial cohort from 2009 to 2011 (before implementation of the algorithm) and the subsequent cohort from 2013 to 2015 (after implementation of the algorithm).
In the time period analyzed for this study anesthesia and intensive care were performed according to standardized protocols. Fluid management was done with lactated Ringer's solution and synthetic colloids. Different blood conservation strategies were used and included consistently cell salvage, standardized application of tranexamic acid and retrograde autologous cardiopulmonary bypass (CPB) priming. Anticoagulant medication was suspended at least 5 days prior to surgery for all elective procedures. Hematocrit measurements were performed using a standard POC blood gas analyzer available in the OR. Indication for red blood cells (RBC) transfusion were a hematocrit (HCT) level below 21% during CPB, below 25% for patients with preserved left ventricular function and 28% for patients with a left ventricular function ≤ 30% and patients undergoing emergency procedures. Standard laboratory tests (blood count, international normalized ratio (INR) / prothrombin time (PT), activated partial thromboplastin time (aPTT) fibrinogen concentration (FIB) were routinely available for guiding transfusion of coagulation blood products. Coagulation management before the implementation of the algorithm was performed based on institutional guidelines in accordance with published recommendations. Kaolin activated clotting time (ACT) measurements were used to guide heparin and protamine management. After heparin reversal and ongoing bleeding prothrombin complex concentrate was applied at a PT ≤ 70% / INR threshold of 1.5 and in selected cases with ongoing major bleeding fresh frozen plasma (FFP) was used to normalize PT/INR. Moreover, fibrinogen concentrate was given below a fibrinogen level of 1 g/l. Platelet concentrates (PLT) were transfused when platelet count was ≤ 100 x 109/lit. PLT were also given in suspected platelet dysfunction. When severe bleeding occurred at the end of the surgical procedure coagulation management was started on an empirical basis by the anesthesiologist in charge.
The SONOCLOT coagulation management algorithm is based on existing literature on this subject and the experience of the authors with the specific POC technique: It considers standard coagulation lab results and platelet function tests and includes the use of the MULTIPLATE analyzer. SONOCLOT measurements consist basically of three dedicated tests:
- A kaolin ACT that is being applied for heparin and protamine administration.
- A glass-bead ACT providing information about the initiation of the clotting process, the propagation of the coagulation and platelet function.
- A glass-bead ACT with heparinase in case the measurement has to be performed under heparin.
First coagulation measurements in each patient undergoing cardiac surgery are executed in the pre-intervention period. The established baseline values trigger the preparation of coagulation blood products that will be applied in the post-interventional period. At the end of the surgical procedure, heparin reversal is performed according to the Bulls protocol. After initial antagonisation with protamine kaolin ACT and glass-bead ACT as well as a heparinase glass-bead ACT are done to primarily detect any residual heparin. For any registered serum heparin the treatment and measurement loop is repeated. In case of an ongoing bleeding after heparin reversal a surgery-related cause has to be excluded and then another treatment and management loop based on glass-bead ACT is initiated and repeated until coagulation has been restored. As soon as results of the standard lab test are available in the postoperative period these are included in the decision making process.
Primary outcome parameters were transfusion rates during the operation and the treatment in the ICU. Secondary outcome parameters included morbidity: an mortality in the postoperative period during the hospital stay.
Statistical analysis will be performed with the software package R. To compare patient-related demographic and perioperative data prior and post algorithm implementation and univariable analysis are performed. Based on the data format and distribution, either Fisher's exact test, t-tests or Wilcoxon rank sum test were applied. For the assessment of the difference of transfusion in the two cohorts and controlling potential influence of other factors two approaches have been chosen. First, after a continuity-corrected log-transformation of the units of RBC given, a sequence of preoperative and procedure related predictors were included in the analysis. To check for multi-colinearity, variance inflation factors are assessed with the R package. Furthermore, to assess the association between potential risk factors and the incidence of postoperative infections a generalized linear model with a binomial link and logit function was chosen and performed with the R package.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| preAlgorithm | – | Device: Standard coagulation managementStandard coagulation management of patients undergoing cardiac surgery |
| postAlgorithm | – | Device: Coagulation management guided by SONOCLOTCoagulation management guided by SONOCLOT of patients undergoing cardiac surgery |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients undergoing cardiac surgery at the Triemli City Hospital
Key inclusion criteria (6 listed)
- Patients undergoing cardiac surgery at the Triemli City Hospital
- Coronary artery bypass grafting
- Valve intervention (Aortic/Mitral/Tricuspid)
- Aortic surgery
- Time period before implementation of a coagulation management guided by SONOCLOT
Key exclusion criteria (2 listed)
- Time period during implementation of a coagulation management guided by SONOCLOT
- Missing data in data base
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Coagulation management guided by SONOCLOTApplication of blood products guided by SONOCLOT measurements | Device | postAlgorithm |
| Standard coagulation managementApplication of blood products based on clinical experience of the anesthesiologist in charge | Device | preAlgorithm |
Primary outcome
Transfusion requirement
Time frame: Postoperative hospital stay; on average 8 days
RBC-Red Blood Cells (units), FFP-Fresh Frozen Plasma (units), PLT-Platelets (units)
2 secondary outcomes
Postoperative complications
Time frame: Postoperative hospital stay; on average 8 days
Mortality
Time frame: Postoperative hospital stay; on average 8 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2018.
- Background: PubMed 28475665Serraino GF, Murphy GJ. Routine use of viscoelastic blood tests for diagnosis and treatment of coagulopathic bleeding in cardiac surgery: updated systematic review and meta-analysis. Br J Anaesth. 2017 Jun 1;118(6):823-833. doi: 10.1093/bja/aex100.
- Background: PubMed 27363652Deppe AC, Weber C, Zimmermann J, Kuhn EW, Slottosch I, Liakopoulos OJ, Choi YH, Wahlers T. Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res. 2016 Jun 15;203(2):424-33. doi: 10.1016/j.jss.2016.03.008. Epub 2016 Mar 26.
- Background: PubMed 26215747Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Kleijnen J. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015 Jul;19(58):1-228, v-vi. doi: 10.3310/hta19580.
- Individual participant dataSharing planned: No
Related trials for Coagulation Disorder, Blood
Recruiting
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
Myeloproliferative Neoplasm, Polycythemia Vera
Not yet recruitingPhase 1
Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias
Immune Thrombocytopenia (ITP)
RecruitingObservational study
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Chronic Myeloproliferative Disorders, Leukemia
Not yet recruitingObservational study
Study of Thyroid Dysfunction in Immune Thrombocytopenic Purpura Patients
Thyroid Dysfunction, Immune Thrombocytopenic Purpura
RecruitingPhase 1/2
A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A
Hemophilia A, Healthy Adult Participants
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michele Genoni, MD, Prof study chair
Triemli City Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coagulation Disorder, Blood, run by Triemli Hospital at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 May 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Transfusion requirement (time frame: Postoperative hospital stay; on average 8 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03482128, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2018.